These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 20377880)
61. High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma. He WP; Wang LL Oncol Lett; 2019 Nov; 18(5):4900-4906. PubMed ID: 31612000 [TBL] [Abstract][Full Text] [Related]
62. Identification and characterization of Bmi-1-responding element within the human p16 promoter. Meng S; Luo M; Sun H; Yu X; Shen M; Zhang Q; Zhou R; Ju X; Tao W; Liu D; Deng H; Lu Z J Biol Chem; 2010 Oct; 285(43):33219-33229. PubMed ID: 20551323 [TBL] [Abstract][Full Text] [Related]
63. PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer. Ma R; Ye X; Cheng H; Ma Y; Cui H; Chang X Gynecol Oncol; 2015 Jun; 137(3):546-52. PubMed ID: 25735255 [TBL] [Abstract][Full Text] [Related]
64. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Davidson B; Reich R; Goldberg I; Gotlieb WH; Kopolovic J; Berner A; Ben-Baruch G; Bryne M; Nesland JM Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247 [TBL] [Abstract][Full Text] [Related]
65. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071 [TBL] [Abstract][Full Text] [Related]
66. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538 [TBL] [Abstract][Full Text] [Related]
67. Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor? Wang L; Allison D; Shukla PS Am J Clin Pathol; 2020 Jun; 154(1):133-141. PubMed ID: 32322877 [TBL] [Abstract][Full Text] [Related]
68. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Engelsen IB; Mannelqvist M; Stefansson IM; Carter SL; Beroukhim R; Øyan AM; Otte AP; Kalland KH; Akslen LA; Salvesen HB Br J Cancer; 2008 May; 98(10):1662-9. PubMed ID: 18475299 [TBL] [Abstract][Full Text] [Related]
69. [Association of Bmi-1 mRNA expression with differentiation, metastasis and prognosis of gastric carcinoma]. Huang KH; Liu JH; Li XX; Song LB; Zeng MS Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):973-5. PubMed ID: 17666329 [TBL] [Abstract][Full Text] [Related]
70. NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer. Shi C; Qin L; Gao H; Gu L; Yang C; Liu H; Liu T Tumour Biol; 2017 Sep; 39(9):1010428317714631. PubMed ID: 28877654 [TBL] [Abstract][Full Text] [Related]
71. Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells. Wu J; Hu D; Yang G; Zhou J; Yang C; Gao Y; Zhu Z J Cell Biochem; 2011 Jul; 112(7):1938-48. PubMed ID: 21445878 [TBL] [Abstract][Full Text] [Related]
72. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Silva J; García V; García JM; Peña C; Domínguez G; Díaz R; Lorenzo Y; Hurtado A; Sánchez A; Bonilla F Breast Cancer Res; 2007; 9(4):R55. PubMed ID: 17711569 [TBL] [Abstract][Full Text] [Related]
73. CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. He WP; Zhou J; Cai MY; Xiao XS; Liao YJ; Kung HF; Guan XY; Xie D; Yang GF BMC Cancer; 2012 Sep; 12():437. PubMed ID: 23020525 [TBL] [Abstract][Full Text] [Related]
74. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351 [TBL] [Abstract][Full Text] [Related]
75. Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability. Dellas A; Puhl A; Schraml P; Thomke SE; Rüschoff J; Mihatsch MJ; Moch H Anticancer Res; 2004; 24(1):361-9. PubMed ID: 15015622 [TBL] [Abstract][Full Text] [Related]
76. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. Baekelandt M; Holm R; Nesland JM; Tropé CG; Kristensen GB J Clin Oncol; 2000 Nov; 18(22):3775-81. PubMed ID: 11078490 [TBL] [Abstract][Full Text] [Related]
77. Biological role and prognostic significance of NAC1 in ovarian cancer. Nakayama K; Rahman MT; Rahman M; Yeasmin S; Ishikawa M; Katagiri A; Iida K; Nakayama N; Miyazaki K Gynecol Oncol; 2010 Dec; 119(3):469-78. PubMed ID: 20869761 [TBL] [Abstract][Full Text] [Related]
78. Increased expression of senescence markers p14(ARF) and p16(INK4a) in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome. Pare R; Shin JS; Lee CS Histopathology; 2016 Sep; 69(3):479-91. PubMed ID: 26843058 [TBL] [Abstract][Full Text] [Related]
79. Expression of bmi-1 protein in cervical, breast and ovarian cancer. Gavrilescu MM; Todosi AM; Aniţei MG; Filip B; Scripcariu V Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1112-7. PubMed ID: 23700898 [TBL] [Abstract][Full Text] [Related]